Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Clinical Safety and Efficacy of FMT in the Treatment of Alzheimer's Disease

To investigate the clinical safety and efficacy of FMT in AD patients, as well as the changes in the gut microbiota of AD patients before and after FMT.

Inclusion Criteria:

• The patients (aged 50-85 years) exhibited cognitive decline persisting for over six months;
• Primarily characterized by recent memory impairment and accompanied by reduced daily living abilities;
• MMSE scores ranging from 3 to 26;
• MRI findings revealed atrophy in the medial temporal lobe, hippocampus, and cerebral cortex, along with widened sulci and fissures.

Exclusion Criteria:

• Patients were excluded if they had severe visual, hearing, or language impairments;
• Tumors;
• hepatic/renal dysfunction.
• with conditions mimicking AD symptoms-such as normal pressure hydrocephalus, vascular dementia (VD or VaD);
• Parkinson's disease dementia (PDD)-were also excluded;
• patients who had participated in clinical drug trials within the past 30 days or consumed folate and vitamin B12 at doses exceeding twice the recommended intake were ineligible.